Comparative Pharmacology
Head-to-head clinical analysis: NYDRAZID versus SODIUM P A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYDRAZID versus SODIUM P A S.
NYDRAZID vs SODIUM P.A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Sodium P.A.S. (para-aminosalicylate) inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid, thereby suppressing bacterial growth.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
4 g orally three times daily (total 12 g/day). For intravenous administration, 4 g (10 mL of 40% solution) diluted in 250 mL of 5% dextrose or normal saline infused over 2-3 hours three times daily.
None Documented
None Documented
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
0.5–1 hour (normal renal function); prolonged to ≥10 hours in renal impairment (requires dose adjustment).
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal ≤10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent